Why the study?
Many individual genetic risk loci associate with multiple diseases, but the molecular basis underlying pleiotropy at the PROCR locus—associated with lower CAD risk but higher VTE risk—remains unclear.
The study elucidates the pleiotropic molecular mechanisms of the PROCR-p.Ser219Gly variant, explaining its divergent effects on lowering CAD risk while increasing VTE risk.
Provides mechanistic insights into PROCR variant pleiotropy; leaves open translation to human risk stratification or therapy.
Many individual genetic risk loci have been associated with multiple common human diseases. However, the molecular basis of this pleiotropy often remains unclear. We present an integrative approach to reveal the molecular mechanism underlying the PROCR locus, associated with lower coronary artery disease (CAD) risk but higher venous thromboembolism (VTE) risk. We identify PROCR-p.Ser219Gly as the likely causal variant at the locus and protein C as a causal factor. Using genetic analyses, human recall-by-genotype and in vitro experimentation, we demonstrate that PROCR-219Gly increases plasma levels of (activated) protein C through endothelial protein C receptor (EPCR) ectodomain shedding in endothelial cells, attenuating leukocyte-endothelial cell adhesion and vascular inflammation. We also associate PROCR-219Gly with an increased pro-thrombotic state via coagulation factor VII, a ligand of EPCR. Our study, which links PROCR-219Gly to CAD through anti-inflammatory mechanisms and to VTE through pro-thrombotic mechanisms, provides a framework to reveal the mechanisms underlying similar cross-phenotype associations.
No takes yet. Share an insight, caveat, or question.
Stacey et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: